An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer

References

• SiegelRNaishadhamDJemalACancer statistics, 2012CA Cancer J Clin2012621102922237781
   PubMed Web of Science ®Google Scholar
• PommervillePJde BoerJGGnRH antagonists in the treatment of advanced prostate cancerCan J Urol20101725063507020398443
   PubMed Web of Science ®Google Scholar
• HugginsCHodgesCVStudies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941J Urol2002168191212050481
   PubMed Web of Science ®Google Scholar
• SartorOAndrogen deprivation – continuous, intermittent, or none at all? N Engl J Med20123671094594622931264
   PubMed Web of Science ®Google Scholar
• SchallyAVArimuraABabaYIsolation and properties of the FSH and LH-releasing hormoneBiochem Biophys Res Commun19714323933994930860
   PubMed Web of Science ®Google Scholar
• SchallyAVArimuraAKastinAJGonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormonesScience19711734001103610384938639
   PubMed Web of Science ®Google Scholar
• SchallyAVLuteinizing hormone-releasing hormone analogues and hormone ablation for prostate cancer: state of the artBJU Int2007100 Suppl 22417594347
   PubMed Web of Science ®Google Scholar
• ReddingTWSchallyAVInhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormoneProc Natl Acad Sci USA19817810650965126458815
   PubMed Web of Science ®Google Scholar
• TolisGAckmanDStellosATumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonistsProc Natl Acad Sci USA1982795165816626461861
   PubMed Web of Science ®Google Scholar
• The Leuprolide Study GroupLeuprolide versus diethylstilbestrol for metastatic prostate cancer.N Engl J Med198431120128112866436700
   PubMed Web of Science ®Google Scholar
• SchröderFCrawfordEDAxcronaKPayneHKeaneTEAndrogen deprivation therapy: past, present and futureBJU Int2012109 Suppl 611222672120
   PubMed Web of Science ®Google Scholar
• ThompsonIMFlare Associated with LHRH-Agonist TherapyRev Urol20013 Suppl 3S10S1416986003
   PubMedGoogle Scholar
• van PoppelHNilssonSTestosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology20087161001100618407326
   PubMed Web of Science ®Google Scholar
• Van PoppelHKlotzLGonadotropin-releasing hormone: an update review of the antagonists versus agonistsInt J Urol201219759460122416801
   PubMed Web of Science ®Google Scholar
• PerssonBEKold OlesenTJensenJKDegarelix: a new approach for the treatment of prostate cancerNeuroendocrinology200990323524419602868
   PubMed Web of Science ®Google Scholar
• ShoreNDAbrahamssonPAAndersonJCrawfordEDLangePNew considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonistsProstate Cancer Prostatic Dis201316171522751146
   PubMed Web of Science ®Google Scholar
• Boccon-GibodLvan der MeulenEPerssonBEAn update on the use of gonadotropin-releasing hormone antagonists in prostate cancerTher Adv Urol20113312714021904569
   PubMedGoogle Scholar
• EngelJBSchallyAVDrug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormoneNat Clin Pract Endocrinol Metab20073215716717237842
   PubMedGoogle Scholar
• StangelbergerASchallyAVDjavanBNew treatment approaches for prostate cancer based on peptide analoguesEur Urol200853589090018201818
   PubMed Web of Science ®Google Scholar
• PinskiJYanoTMillerGSchallyAVBlockade of the LH response induced by the agonist D-Trp-6-LHRH in rats by a highly potent LH-RH antagonist SB-75Prostate19922032132241533453
   PubMed Web of Science ®Google Scholar
• SharmaOPWeinbauerGFBehreHMNieschlagEThe gonadotropin-releasing hormone (GnRH) agonist-induced initial rise of bioactive LH and testosterone can be blunted in a dose-dependent manner by GnRH antagonist in the non-human primateUrol Res19922053173211455564
   PubMedGoogle Scholar
• RickFGSchallyAVBlockNLLHRH antagonist Cetrorelix reduces prostate size and gene expression of proinfammatory cytokines and growth factors in a rat model of benign prostatic hyperplasiaProstate201171773674720945403
   PubMed Web of Science ®Google Scholar
• RickFGSzalontayLSchallyAVCombining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkageJ Urol201218741498150422341819
   PubMed Web of Science ®Google Scholar
• RickFGSchallyAVBlockNLAbi-ChakerAKrishanASzalontayLMechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasiaProstate Epub December 31, 2012
   Google Scholar
• HeinrichESchallyAVBuchholzSDose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138Prostate200868161763177218729085
   PubMed Web of Science ®Google Scholar
• RickFGSaadatSHSzalontayLHormonal manipulation of benign prostatic hyperplasiaCurr Opin Urol2013231172423202285
   PubMed Web of Science ®Google Scholar
• RickFGSchallyAVBlockNLAntagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasiaProc Natl Acad Sci USA201110893755376021321192
   PubMed Web of Science ®Google Scholar
• RickFGSchallyAVSzalontayLAntagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinasesProc Natl Acad Sci USA201210951655166022307626
   PubMed Web of Science ®Google Scholar
• StangelbergerASchallyAVRickFGInhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteinsProstate201272555556521796649
   PubMed Web of Science ®Google Scholar
• Gonzalez-BarcenaDVadillo-BuenfilMGomez-OrtaFResponses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancerProstate199424284927508623
   PubMed Web of Science ®Google Scholar
• Gonzalez-BarcenaDVadillo-BuenflMCortez-MoralesALuteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cordUrology19954522752817531902
   PubMed Web of Science ®Google Scholar
• DebruyneFBhatGGarnickMBAbarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancerFuture Oncol20062667769617155895
   PubMedGoogle Scholar
• BroquaPRivierePJConnPMRivierJEAubertMLJunienJLPharmacological profile of a new, potent, and long-acting gonadotro-pin-releasing hormone antagonist: degarelixJ Pharmacol Exp Ther200230119510211907162
   PubMed Web of Science ®Google Scholar
• KoechlingWHjortkjaerRTankóLBDegarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samplesBr J Clin Pharmacol201070458058720840449
   PubMed Web of Science ®Google Scholar
• Van PoppelHTombalBde la RosetteJJPerssonBEJensenJKKold OlesenTDegarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker – results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancerEur Urol200854480581318538469
   PubMed Web of Science ®Google Scholar
• GittelmanMPommervillePJPerssonBEJensenJKOlesenTKDegarelix Study GroupA 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North AmericaJ Urol200818051986199218801505
   PubMed Web of Science ®Google Scholar
• OzonoSUedaTHoshiSThe efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancerJpn J Clin Oncol201242647748422457321
   PubMed Web of Science ®Google Scholar
• FramptonJELyseng-WilliamsonKADegarelixDrugs200969141967197619747011
   PubMed Web of Science ®Google Scholar
• SteinbergMDegarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancerClin Ther200931Pt 22312233120110043
   PubMed Web of Science ®Google Scholar
• PrincivalleMBroquaPWhiteRRapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonistJ Pharmacol Exp Ther200732031113111817179469
   PubMed Web of Science ®Google Scholar
• ShoreNDExperience with degarelix in the treatment of prostate cancerTher Adv Urol201351112423372607
   PubMedGoogle Scholar
• Mongiat-ArtusPTeillacPAbarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancerExpert Opin Pharmacother20045102171217915461552
   PubMed Web of Science ®Google Scholar
• GuyaderCCéralineJGravierERisk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitorsPLoS One201278e4225222879924
   PubMed Web of Science ®Google Scholar
• KlotzLBoccon-GibodLShoreNDThe efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancerBJU Int2008102111531153819035858
   PubMed Web of Science ®Google Scholar
• Van PoppelHEvaluation of degarelix in the management of prostate cancerCancer Manag Res20102395221188095
   PubMedGoogle Scholar
• US Food and Drug AdministrationFDA Approves Drug for Patients with Advanced Prostate Cancer29 Dec2008 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm117001.htmlAccessed March 2013
   Google Scholar
• European Medicines AgencyAssessment Report for Firmagon4 Mar2009 Available from: http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/000986/WC500023256.pdfAccessed March 2013
   Google Scholar
• TombalBMillerKBoccon-GibodLAdditional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristicsEur Urol201057583684219962227
   PubMed Web of Science ®Google Scholar
• HussainMTangenCMHiganoCSouthwest Oncology Group Trial 9346 (INT-0162). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)J Clin Oncol200624243984399016921051
   PubMed Web of Science ®Google Scholar
• SonpavdeGPondGRBerryWRSerum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapyUrol Oncol201230560761320888271
   PubMed Web of Science ®Google Scholar
• SchröderFHTombalBMillerKChanges in alkaline phos-phatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III studyBJU Int2010106218218719912212
   PubMed Web of Science ®Google Scholar
• SmithMRKlotzLPerssonBEOlesenTKWildeAACardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancerJ Urol201018462313231920952020
   PubMed Web of Science ®Google Scholar
• FridericiaLSThe duration of systole in an electrocardiogram in normal humans and in patients with heart disease. 1920Ann Noninvasive Electrocardiol20038434335114516292
   PubMed Web of Science ®Google Scholar
• ErikssonPHanssonPOErikssonHDellborgMBundle-branch block in a general male population: the study of men born 1913Circulation19989822249425009832497
   PubMed Web of Science ®Google Scholar
• SmithMRKlotzLvan der MeulenEColliETankóLBGonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelixJ Urol201118651835184221944083
   PubMed Web of Science ®Google Scholar
• GittelmanMBrownTMHolm-LarsenTComparison of the impact of degarelix and leuprolide on the health-related quality of life of patients with prostate cancer: results of a 12-month phase III clinical trialUro Today Int J201146 art81
   Google Scholar
• CrawfordEDTombalBMillerKA phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancerJ Urol2011186388999721788033
   PubMed Web of Science ®Google Scholar
• IversenPKarupCvan der MeulenETankóLBHuhtaniemiIHot fushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolideProstate Cancer Prostatic Dis201114218419021445092
   PubMed Web of Science ®Google Scholar
• DamberJETammelaTLIversenPThe effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patientsUrology201280117418022748873
   PubMed Web of Science ®Google Scholar
• de la RosetteJDavisR3rdFrankelDKold OlesenTEfficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancerInt J Clin Pract201165555956621342376
   PubMed Web of Science ®Google Scholar
• RaddinRSWalkoCMWhangYEResponse to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancerAnticancer Drugs201122329930221360851
   PubMed Web of Science ®Google Scholar
• AxcronaKAaltomaaSda SilvaCMAndrogen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamideBJU Int2012110111721172822500884
   PubMed Web of Science ®Google Scholar
• AndersonJAl-AliGWirthMDegarelix versus Goserelin (+Antiandrogen Flare Protection) in the Relief of Lower Urinary Tract Symptoms Secondary to Prostate Cancer: Results from a Phase IIIb Study (NCT00831233)Urol Int Epub December 15, 2012
   Google Scholar
• RaduAPichonCCamparoPExpression of follicle-stimulating hormone receptor in tumor blood vesselsN Engl J Med2010363171621163020961245
   PubMed Web of Science ®Google Scholar
• Ben-JosefEYangSYJiTHHormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR)J Urol1999161397097610022736
   PubMed Web of Science ®Google Scholar
• UlmertDVickersAJScherHIRapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responsesClin Chem Lab Med201250111993199822718641
   PubMed Web of Science ®Google Scholar